FREMONT, Calif., June 14, 2014 /PRNewswire/ -- Zosano Pharma, Inc., a privately held biopharmaceutical company developing products based on its novel transdermal delivery technology, announced that Peter Daddona, Ph.D., Chief Scientific Officer and Executive Vice President, Research & Development, will present data today on its ZP-Glucagon product candidate at the 74th American Diabetes Associations (ADA) Scientific Session, in San Francisco, California.
Dr. Daddona's presentation, entitled "Rapid Glycemic Response with Glucagon Microneedle Patch in Normal Human Volunteers: A Stable, Ready-To-Use Transdermal Patch for Severe Hypoglycemia Treatment," will focus on the company's ZP-Glucagon product candidate as a potential treatment for severe hypoglycemia. ZP-Glucagon uses the company's rapid-acting transdermal technology, which is being developed as an alternative to injections, to deliver glucagon, a compound that has been proven to increase blood glucose in insulin-dependent diabetic patients with severe hypoglycemia.
About Zosano Pharma
Zosano Pharma, Inc. is a privately held biopharmaceutical company and a pioneer in the field of transdermal drug delivery. Zosano is developing products with a rapid onset using its proprietary microneedle patch system. Zosano seeks to develop products with significant commercial potential both independently and in collaboration with strategic partners. Zosano's microneedle patch delivers therapeutic compounds through the skin and provides rapid systemic drug delivery in a convenient, needlefree and painfree system. Zosano's microneedle patch system has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. Learn more at www.zosanopharma.com.
SOURCE Zosano Pharma, Inc.